PolyPid Ltd. SEC Filings

PolyPid Ltd. granted 149,000 stock options to Chief Executive Officer Akselbrad Dikla Czaczkes. The options relate to Ordinary Shares at an exercise price of $4.46 per share, vest quarterly from May 11, 2026 through May 11, 2030, and expire on July 15, 2036.

PolyPid Ltd. held an Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where a quorum was present and shareholders approved all four proposals. These included re-electing Kost Forer Gabbay & Kasierer as independent auditors, re-electing eight directors and approving their compensation, amending non-executive directors’ annual option grants, and approving an option grant for Chief Executive Officer Dikla Czaczkes Akselbrad.

Separately, on May 11, 2026, the board approved increasing the ordinary shares reserved for issuance under PolyPid’s Amended and Restated 2012 Share Option Plan by 1,500,000, from 3,512,403 to 5,012,403 shares. The plan sets eligibility for employees, officers, directors, consultants and other service providers, a standard four-year vesting schedule, repurchase rights upon termination for cause, and detailed tax and transfer rules, including Israeli and U.S. tax sub-plans.

PolyPid Ltd. is calling an annual and extraordinary general meeting of shareholders on July 15, 2026 in Petach Tikva, Israel. Shareholders of record at the close of business on June 15, 2026 may vote in person or by proxy.

On the agenda are proposals to re-elect Kost Forer Gabbay & Kasierer (EY) as independent auditors, re-elect eight directors and approve their cash and option compensation, amend the terms of annual option grants for non-executive directors, and grant options over up to 149,000 ordinary shares to CEO Dikla Czaczkes Akselbrad. Shareholders will also discuss, but not vote on, the 2025 audited financial statements and Form 20-F.

PolyPid Ltd. has completed its New Drug Application submission to the U.S. FDA for D-PLEX100, its lead drug candidate to prevent surgical site infections in patients undergoing colorectal surgery. The FDA review is following a PDUFA timeline with a target action date in the first quarter of 2027.

The NDA is backed by the Phase 3 SHIELD II trial, where D-PLEX100 met its primary and all key secondary endpoints and showed a 60% relative risk reduction in surgical site infections versus standard of care (p=0.0013). D-PLEX100 delivers local, controlled release of doxycycline at the wound site for about 30 days and has FDA Breakthrough Therapy, Fast Track and Qualified Infectious Disease Product designations, supporting eligibility for Priority Review.

PolyPid Ltd. reported a net loss of $7,728 thousand for the first quarter of 2026, slightly improved from $8,268 thousand a year earlier. Operating expenses totaled $7,760 thousand, driven mainly by research and development of D-PLEX₁₀₀, which is now under an initiated NDA submission to the FDA.

Cash and cash equivalents were $8,888 thousand as of March 31, 2026, with total current assets of $12,560 thousand. Shareholders’ equity stood at $8,780 thousand, supported by additional paid-in capital of $318,008 thousand. Management highlighted late-stage U.S. commercial partnership discussions and reiterated expectations that existing cash resources can fund operations into the second half of 2026.

PolyPid Ltd. filed an amendment to its Schedule 13G/A disclosing that Rosalind Advisors Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon each report shared beneficial voting and dispositive power over 5,384,813 shares, representing 9.9% of the class based on 18,204,002 ordinary shares outstanding as of December 31, 2025.

The filing states 597,926 shares are directly held and an additional 4,786,887 shares are issuable upon exercise of warrants subject to a blocker that prevents exercise to the extent it would increase beneficial ownership above 9.99%. The advisor and named individuals disclaim beneficial ownership beyond their advisory roles.

Polypid Ltd. ownership update: Aurum Ventures M.K.I. Ltd. reports beneficial ownership of 5,001,561 Ordinary Shares, consisting of 3,550,133 outstanding shares plus 1,451,428 shares issuable upon currently exercisable warrants. The filing bases its percent on 19,083,236 Ordinary Shares outstanding as of February 19, 2026, yielding 24.4% of the class; the reporting person notes warrant "blocker" provisions that limit exercise above 9.9% at any time.

PolyPid Ltd. director Jacobovitz Yitzchak Shlomo has filed an initial Form 3, which is the baseline disclosure of his ownership in the company as a reporting insider. The filing shows no recent stock purchases, sales, or other transactions, and contains no derivative holdings.

PolyPid Ltd. director Robert Benjamin Stein reported his existing holdings of stock options to purchase Ordinary Shares. These options cover individual blocks such as 312 shares at an exercise price of 11.4000 per share expiring on 2033-05-05 and 6,500 shares at 4.2400 per share expiring on 2034-07-02. Another grant for 14,440 underlying shares has an exercise price of 2.6700 per share and expires on 2035-06-25, with vesting on a quarterly basis through 2029. Several earlier grants are already fully vested, reflecting established equity-based compensation rather than new market transactions.